Chuck, I don't see how anyone that watches your videos can think FASTgraphs is difficult to use. You do a fantastic job in explaining the features and demonstrating the simple usefulness with real-time valuations. I appreciate both your product and your videos!
Sure but first I used Fastgraphs and later on discovered the RUclips channel. I didnt know about half of the features of Fastgraphs before watching these videos and I bet many users of Fastgraphs dont know about this channel or many features. It would be good to implement some tutorial videos directly to fastgraphs. Lets say you are on the page forecasting and there will be a button to play tutorial video on every function that page offers.
Dividend growth is around .14 cents per year. I just brought in today. This company pays more than 3M, McDonald's, Kimberly-Clarke, IBM, etc. This is my highest paying stock and the highest paying dividend increase stock that I own in my financial portfolio.
I always learn alot from you. I own alot of amgen. Have owned it for along time. When price drops like this in any stock some of us have a tendency to think about selling some. Your analysis makes me realize this stock is still a solid investment. Thx much.
J W: I do like to point out that not all Price drops are the same. If the stock price Is dropping from significant overvaluation then my inclination is to sell. However, if a stock is already attractively valued or even undervalued such as Amgen, my reaction is a value investor is to buy not sell. Hope that adds clarity, Chuck
I am a buy & hold, old fashion guy, I bought couple hundred AMGN, when it was at ~$160 level, I will buy more when the price became cheaper hopefully during Sept-Oct period.
Really good video Mr. Chuck Carnevale. I thoroughly enjoy your analysis methods. Out my DGI Portfolio HealthCare is prominent at 22% (probably too prominent but their recent, current valuations, and earnings outlooks have enticed me to purchase - I will have to refrain but some deals have been very good). I will say that I own stock of the following Healthcare Companies: JNJ, BMY, ABBV, PFE, VTRS, AMGN, + VHT (ETF). Healthcare related stocks I also own are CAH, WAB and KR but they are more in the insurance-grocery realm though they do have important healthcare ins + drug sales components. Thank you for your very valuable work!
Chuck, Amgen's revenue, net income, and free cash flows are pretty much stagnant over the last 4-5 years (in absolute terms). However, they have been aggressively buying back shares, which gives you a growth in revenue, net income, and free cash flows (per share basis). Would you still consider they have been growing over the last 4-5 years at 8% rate ? (although their total revenues, net income, and free cash flows are either stagnant or declining?). Excellent video as always. Thanks,- Ali
Mr. international : I am long in all 3 but for different reasons. I have long liked Amgen for its consistent growth, Bristol-Myers from a low valuation and AbbVie for low valuation high dividend yield and growth. Although they are generally in the same sector, their businesses are quite different. I think you should also consider that finding good value is hard to do today. Hope that helps, Chuck
Love the wisdom. But I have a question. HDV and SPYD hold many of the stocks you are high on. Walgreens and Amgen, for example. Why not just buy an ETF that has a bunch of these in it? Or.... What would be the situation when that would be a better option? Thanks for the advice.
Patrick I personally prefer to build my own portfolio. I have never seen a package product such as an ETF, CEF, mutual fund etc. that does not contain overvalued stocks. Nevertheless, that is simply my opinion and preference. Regards, Chuck
@@FASTgraphs here is why I ask. I have been a follower of Dave Ramsey for many years. As you know, he loves funds and is against individual stocks. But, I absolutely see your point. That is why I have shifted to the core satellite portfolio. Any advice on how to square this circle would be greatly appreciated.
Hey Chuck. I have an off-topic question for you. I was showing FG to a friend. We were looking at a 20yr historical graph of MO, Altria, showing price correlated with fundamentals. We noticed that FG shows different prices than the actual prices paid for the stock. For example, in March of 2007 MO was trading in the 80's and yet the FG shows it trading in the 20's. What is the explanation? Thanks.
Barry, Our data provider FactSet adjusts stock prices for spinoffs and splits. As you know Phillip Morris now known as Altria spun off Kraft and Philip Morris International. Therefore, the graph reflects the existing company with historical prices adjusted to reflect the effect of those spinoffs. In the new version of FAST Graphs you will be able to choose between the adjusted prices versus the historical actuals. Therefore, you will be able to see what companies like Altria look like historically prior to the spinoffs and/or what they look like after the spinoffs. I hope that clarifies it. Regards, Chuck
How do you believe your investment strategies should change as you age? I’m 22. Should I focus on quality companies trading under intrinsic value that offer possible double digit returns, smaller companies with larger growth prospects, GARP, fast growing companies with higher multiples, etc.? As always, great videos. FAST Graphs has been incredibly useful and convenient. Thanks
Kyle: I basically like your plan. Yes I would look for growth over income at your age, but I would still try to keep risk under control by being very strict with valuation. I'm glad you're finding FAST Graphs of value to you. Regards, Chuck
no, Amgen is very generous with its shareholders regarding dividends and share buybacks as I indicated in the video. Also, the company generates strong free cash flow. Regards, Chuck
The only stocks in my portfolio/watchlist I feel are at or below fair value right now are LMT, BMY and AMGN (honorable mention INTC). I took the post-earnings dip as an opportunity to buy shares this morning at $229. Some moderate price forecasts I made projected about an 11% rate of return at current prices, so as long as AMGN performs reasonably over the next 5 years it should be a solid hold. That sneak peak of the new FastGraphs looks good. As someone who works in the tech space, I know good software takes time to write and test to work out any bugs or kinks. I'm sure the wait will be worth it, we just all gotta be patient.
Chuck, great video as always. Very timely. Question, what is your comfort level in terms a sectors percentage of your portfolio? I own BMY, ABBV, MRK, PFE, JNJ, UNH, ANTM, AMGN. These stocks makes up 21% of my portfolio. Thank you sir
YKC C: that is a lot of concentration essentially in healthcare. However, each of those businesses operate in their own specific areas of healthcare. Nevertheless, that is a lot of healthcare. On the other hand, in today's overheated market healthcare is 1 of the few areas that are attractively valued. In my opinion valuation trumps diversification. Stated differently, I believe the best way to minimize long-term risk is to invest with a margin of safety. Diversification is important, and in my opinion, not as. Regards, Chuck
the total annual ROR is not with dividends reinvested. However, FAST Graphs provides the option to show performance with dividends reinvested. Personally, I believe that seeing the rate of return separately is more reflective of how the actual business has done. Nevertheless, you can run the calculation both ways. Regards, Chuck
Chuck, since AMGN has been trading at a "Normal P/E" of ~14 over last 10 to 15 years, wouldn't an investor need to buy at a lower "Blended P/E" than that to have a margin of safety? For instance, a blended P/E of 12.6 would give 10% cushion.
Jason: the bigger the margin of safety better. However, sometimes you just have to take what the market gives you. I would not call Amgen extremely cheap, but on the other hand I would do consider it reasonably priced. With all that said a better margin of safety would be welcome. Regards, Chuck
Paul: I believe you could say that about almost any business. Nevertheless, there a lot of fish in the sea. If you don't like biotech that you should follow your instincts. Nobody needs to own any stock or sector. Regards, Chuck
They are cheap because they will loose big income due to loosing patent ( expired) on humira which big chunk of their income Next year. Once that get fairly priced in , they will buy for pipeline growth
Chuck, I don't see how anyone that watches your videos can think FASTgraphs is difficult to use. You do a fantastic job in explaining the features and demonstrating the simple usefulness with real-time valuations. I appreciate both your product and your videos!
thanks
Sure but first I used Fastgraphs and later on discovered the RUclips channel. I didnt know about half of the features of Fastgraphs before watching these videos and I bet many users of Fastgraphs dont know about this channel or many features. It would be good to implement some tutorial videos directly to fastgraphs. Lets say you are on the page forecasting and there will be a button to play tutorial video on every function that page offers.
Dividend growth is around .14 cents per year. I just brought in today. This company pays more than 3M, McDonald's, Kimberly-Clarke, IBM, etc. This is my highest paying stock and the highest paying dividend increase stock that I own in my financial portfolio.
Chuck, you are the personification of someone who impresses without even trying. Thanks for the video!
Buyed yesterday. Doubled my position from 2 to 4 shares.
Great Video again, thanks.
"Bought"
@@jamesdarnell8568 Thanks.
I always learn alot from you. I own alot of amgen. Have owned it for along time. When price drops like this in any stock some of us have a tendency to think about selling some. Your analysis makes me realize this stock is still a solid investment. Thx much.
J W: I do like to point out that not all Price drops are the same. If the stock price Is dropping from significant overvaluation then my inclination is to sell. However, if a stock is already attractively valued or even undervalued such as Amgen, my reaction is a value investor is to buy not sell. Hope that adds clarity, Chuck
I am a buy & hold, old fashion guy, I bought couple hundred AMGN, when it was at ~$160 level, I will buy more when the price became cheaper hopefully during Sept-Oct period.
Really good video Mr. Chuck Carnevale. I thoroughly enjoy your analysis methods. Out my DGI Portfolio HealthCare is prominent at 22% (probably too prominent but their recent, current valuations, and earnings outlooks have enticed me to purchase - I will have to refrain but some deals have been very good). I will say that I own stock of the following Healthcare Companies: JNJ, BMY, ABBV, PFE, VTRS, AMGN, + VHT (ETF). Healthcare related stocks I also own are CAH, WAB and KR but they are more in the insurance-grocery realm though they do have important healthcare ins + drug sales components. Thank you for your very valuable work!
Спасибо! Very interesting!
Super presentation Chuck. I just finished swapping out a little JNJ for AMGN.
Sven Carlin and Chuck what the team can be to get best value ever . 👏
Chuck, Amgen's revenue, net income, and free cash flows are pretty much stagnant over the last 4-5 years (in absolute terms). However, they have been aggressively buying back shares, which gives you a growth in revenue, net income, and free cash flows (per share basis). Would you still consider they have been growing over the last 4-5 years at 8% rate ? (although their total revenues, net income, and free cash flows are either stagnant or declining?). Excellent video as always. Thanks,- Ali
I went for BMY and ABBV, but AMGN would be good if i were a diversifying investor !
Mr. international : I am long in all 3 but for different reasons. I have long liked Amgen for its consistent growth, Bristol-Myers from a low valuation and AbbVie for low valuation high dividend yield and growth. Although they are generally in the same sector, their businesses are quite different. I think you should also consider that finding good value is hard to do today. Hope that helps, Chuck
Great Video, thanks for the insight!
Great video as usual Chuck. I think Cigna need the Clorox treatment next.
This was a very good video. Thanks
thanks
First from Germany !
Verdammt seist du!
@dagobert76 möge der Glückskreuzer mit uns sein, das wir bald Kopfüber in das Geld eintauchen können
I would Amgen buy for under 200. Cigna is very interesting after the drop yesterday. Solid business and cashflow.
Cigna looks great. Huge growth ahead for them. Insanely low payout ratio.
big pharma and finance seem to be the 2 sectors where you can find value these days. I plan to increase my BMY and MFC positions tomorrow.
Excellent video, could you check APD next please. Thanks
Chuck what are your thoughts on cardinal health? It dropped 13pct on miss
I like Cardinal Health long-term. the opioid settlements have everyone spooked temporarily
Thanks for content
Do you speculate in any beginning stage stocks like HYLN with no revenue yet?
Love the wisdom. But I have a question. HDV and SPYD hold many of the stocks you are high on. Walgreens and Amgen, for example. Why not just buy an ETF that has a bunch of these in it? Or.... What would be the situation when that would be a better option? Thanks for the advice.
Patrick I personally prefer to build my own portfolio. I have never seen a package product such as an ETF, CEF, mutual fund etc. that does not contain overvalued stocks. Nevertheless, that is simply my opinion and preference. Regards, Chuck
@@FASTgraphs here is why I ask. I have been a follower of Dave Ramsey for many years. As you know, he loves funds and is against individual stocks. But, I absolutely see your point. That is why I have shifted to the core satellite portfolio. Any advice on how to square this circle would be greatly appreciated.
Waiting for your comments on Cigna. Great video by the way. Take care Chuck
FYI I am long Cigna and like it at these levels. Regards, Chuck
REGN just posted monster results. I think it might be worth a revisit sometime.
Hey Chuck. I have an off-topic question for you. I was showing FG to a friend. We were looking at a 20yr historical graph of MO, Altria, showing price correlated with fundamentals. We noticed that FG shows different prices than the actual prices paid for the stock. For example, in March of 2007 MO was trading in the 80's and yet the FG shows it trading in the 20's. What is the explanation? Thanks.
Barry,
Our data provider FactSet adjusts stock prices for spinoffs and splits. As you know Phillip Morris now known as Altria spun off Kraft and Philip Morris International. Therefore, the graph reflects the existing company with historical prices adjusted to reflect the effect of those spinoffs.
In the new version of FAST Graphs you will be able to choose between the adjusted prices versus the historical actuals. Therefore, you will be able to see what companies like Altria look like historically prior to the spinoffs and/or what they look like after the spinoffs. I hope that clarifies it.
Regards, Chuck
How do you believe your investment strategies should change as you age? I’m 22. Should I focus on quality companies trading under intrinsic value that offer possible double digit returns, smaller companies with larger growth prospects, GARP, fast growing companies with higher multiples, etc.?
As always, great videos. FAST Graphs has been incredibly useful and convenient. Thanks
Kyle: I basically like your plan. Yes I would look for growth over income at your age, but I would still try to keep risk under control by being very strict with valuation. I'm glad you're finding FAST Graphs of value to you. Regards, Chuck
what do you think about its consistently negative retained earnings and does it concern you? Thank you
no, Amgen is very generous with its shareholders regarding dividends and share buybacks as I indicated in the video. Also, the company generates strong free cash flow. Regards, Chuck
The only stocks in my portfolio/watchlist I feel are at or below fair value right now are LMT, BMY and AMGN (honorable mention INTC). I took the post-earnings dip as an opportunity to buy shares this morning at $229. Some moderate price forecasts I made projected about an 11% rate of return at current prices, so as long as AMGN performs reasonably over the next 5 years it should be a solid hold.
That sneak peak of the new FastGraphs looks good. As someone who works in the tech space, I know good software takes time to write and test to work out any bugs or kinks. I'm sure the wait will be worth it, we just all gotta be patient.
thanks for the support, regards, Chuck
Chuckster greatest!
Chuck, great video as always. Very timely. Question, what is your comfort level in terms a sectors percentage of your portfolio? I own BMY, ABBV, MRK, PFE, JNJ, UNH, ANTM, AMGN. These stocks makes up 21% of my portfolio. Thank you sir
I recommend watching Cameron Stewart on a few of those, e.g., Merck.
YKC C: that is a lot of concentration essentially in healthcare. However, each of those businesses operate in their own specific areas of healthcare. Nevertheless, that is a lot of healthcare. On the other hand, in today's overheated market healthcare is 1 of the few areas that are attractively valued. In my opinion valuation trumps diversification. Stated differently, I believe the best way to minimize long-term risk is to invest with a margin of safety. Diversification is important, and in my opinion, not as. Regards, Chuck
Does the Total Annulal ROR on graph include dividends reinvested or not?
the total annual ROR is not with dividends reinvested. However, FAST Graphs provides the option to show performance with dividends reinvested. Personally, I believe that seeing the rate of return separately is more reflective of how the actual business has done. Nevertheless, you can run the calculation both ways. Regards, Chuck
Chuck, since AMGN has been trading at a "Normal P/E" of ~14 over last 10 to 15 years, wouldn't an investor need to buy at a lower "Blended P/E" than that to have a margin of safety? For instance, a blended P/E of 12.6 would give 10% cushion.
Jason: the bigger the margin of safety better. However, sometimes you just have to take what the market gives you. I would not call Amgen extremely cheap, but on the other hand I would do consider it reasonably priced. With all that said a better margin of safety would be welcome. Regards, Chuck
'05-'07 valuations were still highn no? Buybacks would've been better after/during the recession, right?
cliftt: technically, I would say you are correct.
CAH CI and Activision !
Amgen is good but for me BMY is bedder at the moment.Buying every Month more.
"better"
AMGN is looking good right now. Down 13% 1 yr
I think Cigna is the other one to buy on overreaction
Bought 4 more this morning at $200. Would love to see Chuck cover it in depth like this one.
I own Johnson & Johnson, Abbvie Inc, Bristol-Meyers Squibb, and Amgen stock. Stay away from Pfizer stock (major capital depreciation). Smile.
At a $ 190 price tag I would consider AMGN. Until then BMY and/or ABBV are more to my taste.
What's the safety of margin? 10% of it's normal trading PE?
the margin of safety would be anything below the intrinsic value. The more the better. Regards, Chuck
AMGEN AT $201 IS A BUY?!
These biotechs can be one failed clinical trial away from Armageddon. I've seen it happen way too often....
Paul: I believe you could say that about almost any business. Nevertheless, there a lot of fish in the sea. If you don't like biotech that you should follow your instincts. Nobody needs to own any stock or sector. Regards, Chuck
They are cheap because they will loose big income due to loosing patent ( expired) on humira which big chunk of their income Next year. Once that get fairly priced in , they will buy for pipeline growth
I think you have it confused. Humira is a abbv drug. Yes patent cliff coming but abbv has done an excellent job with acquisitions to offset
"lose" "losing"
@@superstar80ch you are right I got confused.